Announcement: Neuroimmune abnormalities identified as potential driver of fibromyalgia pathology

GMJ
By
Prof. Giorgi Pkhakadze, MD, MPH, PhD
0 Min Read
Illustration of the brain and central nervous system with immune cell activation markers representing neuroimmune dysfunction in fibromyalgia
Research from the University of Barcelona suggests neuroimmune dysfunction in the central nervous system drives fibromyalgia pathology. This mechanistic insight may enable biomarker-driven diagnosis and targeted therapeutic development. — Photo by ROCKETMANN TEAM on Pexels (Pexels License)
1 min read|50 words

New research from the University of Barcelona reveals that neuroimmune abnormalities in the central nervous system may be the key driver of fibromyalgia—not peripheral tissue damage. This mechanistic insight could transform how millions of patients are diagnosed and treated. Read the analysis:

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze, MD, MPH, PhD
Follow:
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
World-First Prenatal Surgery Saves Identical Twins from Life-Threatening Pregnancy Condition

Identical twins Nancy and Margo have become the first patients to survive…

Infection-Driven Cancer Prevention: Knowledge Without Implementation Is Epidemiological Theater

Recent epidemiology confirms that preventable infections cause one in eight cancers globally—yet…

ARPA-H funds $160 million gene-editing push for rare diseases after administrative delays

The U.S. Advanced Research Projects Agency for Health (ARPA-H) is awarding $160…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

© 2026 GMJ News · PHIG · Sheni Network